Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy
Journal of Nanobiotechnology · 2024
DOI: 10.1186/s12951-024-02575-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nanobiotechnology, 2024. Verfasst von Kangkang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Curcumin, MicroRNAs, Nanoparticles, Reactive Oxygen Species. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation, Key Project of Innovative Teaching Laboratory of Qingdao University in 2022.
Abstract (Originalsprache)
Considerable attention has been directed towards exploring the potential efficacy of miR-155 in the realm of cancer immunotherapy. Elevated levels of miR-155 in dendritic cells (DCs) have been shown to enhance their maturation, migration, cytokine secretion, and their ability to promote T cell activation. In addition, overexpression of mir155 in M2 macrophages boost the polarization towards the M1 phenotype. Conversely, miR-155 has the propensity to induce the accumulation of immunosuppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor tissue. To account for this discrepancy, it is imperative to get help from a drug that could deal with immunosuppressive effect. Curcumin (CUR) exhibits the capacity to prompt Tregs converse into T helper 1 cells, fostering the polarization of M2 tumor-associated macrophage towards the M1 phenotype, and impeding the recruitment and aggregation of MDSCs within the tumor microenvironment. Nonetheless, CUR is known to exert an immunosuppressive impact on DCs by hindering the expression of maturation markers, cytokines, and chemokines, thereby prevent DCs response to immunostimulatory agents. Hence, a reactive oxygen species/glutathione dual responsive drug conveyance platform (CUR/miR155@DssD-Hb NPs) was devised to co-deliver CUR and miR155, with the aim of exploring their synergistic potential in bolstering a sustained and robust anti-tumor immune response. In vitro and in vivo results have suggested that CUR/miR155@DssD-Hb NPs can effectively inhibit the viability of 4T1 and B16F10 tumor cells, trigger the release of damage associated molecular patterns, stimulate DCs maturation, subsequent activation of CD8 + T cells, diminish immunosuppressive cell populations (MDSCs, Tregs, M2 TAMs and exhausted T cells), promote the formation of long-term immunity and lessen the formation of metastatic nodules in the lungs. In summary, the co-delivery system integrating CUR and miR155 (CUR/miR155@DssD-Hb NPs) demonstrates promise as a promising strategy for the immunotherapy of melanoma and triple negative breast cancer. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medicine, Qingdao University, Qingdao, China.
- Pharmacy Department, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
- Department of Neurosurgery, Affiliated Hospital of Qingdao University, Qingdao, China.
- School of Basic Medicine, Qingdao University, Qingdao, China. chenxuehong@qdu.edu.cn.
Förderung
- Shandong Provincial Natural Science Foundation
- Key Project of Innovative Teaching Laboratory of Qingdao University in 2022
Zitieren
APA
Li, K., Wang, J., Xie, Y., Lu, Z., Sun, W., Wang, K., Liang, J., & Chen, X. (2024). Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-024-02575-5
Vancouver
Li K, Wang J, Xie Y, Lu Z, Sun W, Wang K, et al. Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy. Journal of Nanobiotechnology. 2024. doi:10.1186/s12951-024-02575-5
BibTeX
@article{Li2024,
author = {Li, Kangkang and Wang, Juan and Xie, Yi and Lu, Ziyao and Sun, Wen and Wang, Kaixuan and Liang, Jinxin and Chen, Xuehong},
title = {Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy},
journal = {Journal of Nanobiotechnology},
year = {2024},
doi = {10.1186/s12951-024-02575-5}
}
EUVIMED